[On the effect of a new cytostatic drug in chronic myeloses and polycythemias].
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001966:Bromine; D002908:Chronic Disease; D004906:Erythrocyte Count; D004920:Erythropoiesis / Q000187:drug effects; D005260:Female; D006801:Humans; D007951:Leukemia, Myeloid / Q000188:drug therapy*; D007958:Leukocyte Count / Q000627:therapeutic use; D008297:Male; D051379:Mice; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D010885:Pipobroman / Q000008:administration & dosage / Q000627:therapeutic use; D011087:Polycythemia Vera / Q000188:drug therapy*; D055728:Primary Myelofibrosis / Q000188:drug therapy*; D011422:Propionates / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D010879:Piperazines; D011422:Propionates; D010885:Pipobroman; D001966:Bromine
Zur Wirkung eines neuen Zytostatikums bei chronischen Myelosen und Polyzythämien.